Prevalence of Comorbidities and Risk Factors for Comorbidities in Patients with Spondyloarthritis in Latin America: A Comparative Study with the General Population and Data from the ASAS-COMOSPA Study

REFERENCES

1. 1.↵
   1. Ogdie A,
   2. Schwartzman S,
   3. Husni ME

   . Recognizing and managing comorbidities in psoriatic arthritis. Curr Opin Rheumatol 2015;27:118–26.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Sun LM,
   2. Muo CH,
   3. Liang JA,
   4. Chang SN,
   5. Sung FC,
   6. Kao CH

   . Increased risk of cancer for patients with ankylosing spondylitis: a nationwide population-based retrospective cohort study. Scand J Rheumatol 2014;43:301–6.

   OpenUrl
3. 3.↵
   1. Germano V,
   2. Cattaruzza MS,
   3. Osborn J,
   4. Tarantino A,
   5. Di Rosa R,
   6. Salemi S,
   7. et al.

   Infection risk in rheumatoid arthritis and spondyloarthropathy patients under treatment with DMARDs, corticosteroids and TNF-α antagonists. J Transl Med 2014;12:77.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Prati C,
   2. Claudepierre P,
   3. Pham T,
   4. Wendling D

   . Mortality in spondyloarthritis. Joint Bone Spine 2011;78:466–70.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Bremander A,
   2. Petersson IF,
   3. Bergman S,
   4. Englund M

   . Population-based estimates of common comorbidities and cardiovascular disease in ankylosing spondylitis. Arthritis Care Res 2011;63:550–6.

   OpenUrlCrossRef
6. 6.↵
   1. Gherghe AM,
   2. Dougados M,
   3. Combe B,
   4. Landewé R,
   5. Mihai C,
   6. Berenbaum F,
   7. et al.

   Cardiovascular and selected comorbidities in early arthritis and early spondyloarthritis, a comparative study: results from the ESPOIR and DESIR cohorts. RMD Open 2015;1(1):e000128.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Mathieu S,
   2. Motreff P,
   3. Soubrier M

   . Spondyloarthropathies: an independent cardiovascular risk factor? Joint Bone Spine 2010;77:542–5.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. McCarey D,
   2. Sturrock RD

   . Comparison of cardiovascular risk in ankylosing spondylitis and rheumatoid arthritis. Clin Exp Rheumatol 2009;27:S124–6.

   OpenUrlPubMed
9. 9.↵
   1. Essers I,
   2. Stolwijk C,
   3. Boonen A,
   4. De Bruin ML,
   5. Bazelier MT,
   6. de Vries F,
   7. et al.

   Ankylosing spondylitis and risk of ischaemic heart disease: a population-based cohort study Ann Rheum Dis 2016;75:203–9.

   OpenUrl
10. 10.↵
    1. Carmona L,
    2. Hernandez-Garcia C,
    3. Vadillo C,
    4. Pato E,
    5. Balsa A,
    6. Gonzalez-Alvaro I,
    7. et al.

    Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol 2003;30:1436–9.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Franks AL,
    2. Slansky JE

    . Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer. Anticancer Res 2012;32:1119–36.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    1. Molto A,
    2. Enchuto A,
    3. van der Heijde D,
    4. Landewe R,
    5. van den Bosch F,
    6. Bautista-Molano W,
    7. et al.

    Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study. Ann Rheum Dis 2016;75:1016–23.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    1. Schargrodsky H,
    2. Hernandez-Hernandez R,
    3. Champagne BM,
    4. Silva H,
    5. Vinueza R,
    6. Silva Aycaquer LC,
    7. et al.

    CARMELA: assessment of cardiovascular risk in seven Latin American cities. Am J Med 2008;121:58–65.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Hernandez-Hernandez R,
    2. Silva H,
    3. Velasco M,
    4. Pellegrini F,
    5. Macchia A,
    6. Escobedo J,
    7. et al.

    Hypertension in seven Latin American cities: the Cardiovascular Risk Factor Multiple Evaluation in Latin America (CARMELA) study. J Hypertens 2010;28:24–34.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Raviglione M

    . Global tuberculosis report 2015, World Health Organization. [Internet. Accessed November 9, 2017.] Available from: http://apps.who.int/iris/bitstream/10665/191102/1/9789241565059_eng.pdf
16. 16.↵
    1. Bray F,
    2. Ren JS,
    3. Masuyer E,
    4. Ferlay J

    . Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer 2013;132:1133–45.

    OpenUrlCrossRefPubMed
17. 17.↵
    1. Ferlay J,
    2. Soerjomataram I,
    3. Ervik M,
    4. Forman D,
    5. Bray F

    , editors. GLOBOCAN 2012: Estimated cancer Incidence, Mortality and prevalence Worldwide in 2012. International Agency for Research on Cancer, World Health Organization. 2013. [Internet. Accessed November 9, 2017.] Available from: http://globocan.iarc.fr
18. 18.↵
    1. Wilson EB

    . Probable inference, the law of succession, and statistical inference. J Am Stat Assoc 1927;22:209–12.

    OpenUrlCrossRef
19. 19.↵
    1. Wallis S

    . Binomial confidence intervals and contingency tests: mathematical fundamentals and the evaluation of alternative methods. J Quant Linguist 2013;20:178–208.

    OpenUrlCrossRef
20. 20.↵
    1. Mathieu S,
    2. Gossec L,
    3. Dougados M,
    4. Soubrier M

    . Cardiovascular profile in ankylosing spondylitis: a systematic review and meta-analysis. Arthritis Care Res 2011;63:557–63.

    OpenUrlCrossRef
21. 21.↵
    1. Han C,
    2. Robinson DW,
    3. Hackett MV,
    4. Paramore LC,
    5. Fraeman KH,
    6. Bala MV

    . Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 2006;33:2167–72.

    OpenUrlAbstract/FREE Full Text
22. 22.↵
    1. Heslinga SC,
    2. Van den Oever IA,
    3. Van Sijl AM,
    4. Peters MJ,
    5. Van der Horst-Bruinsma IE,
    6. Smulders YM,
    7. et al.

    Cardiovascular risk management in patients with active ankylosing spondylitis: a detailed evaluation. BMC Musculoskelet Disord 2015;16:80.

    OpenUrlCrossRefPubMed
23. 23.↵
    1. Haroon NN,
    2. Paterson JM,
    3. Li P,
    4. Inman RD,
    5. Haroon N

    . Patients with ankylosing spondylitis have increased cardiovascular and cerebrovascular mortality a population-based study. Ann Intern Med 2015;163:409–16.

    OpenUrlCrossRefPubMed
24. 24.↵
    1. Sundstrom B,
    2. Johansson G,
    3. Johansson I,
    4. Wallberg-Jonsson S

    . Modifiable cardiovascular risk factors in patients with ankylosing spondylitis. Clin Rheumatol 2014:33:111–7.

    OpenUrlCrossRefPubMed
25. 25.↵
    1. Connolly M,
    2. Nunn P

    . Women and tuberculosis. World Health Stat Q 1996;49:115–9.

    OpenUrlPubMed
26. 26.↵
    1. Munayco CV,
    2. Mujica OJ,
    3. Leon FX,
    4. del Granado M,
    5. Espinal MA

    . Social determinants and inequalities in tuberculosis incidence in Latin America and the Caribbean. Rev Panam Salud Publica 2015;38:177–85.

    OpenUrl
27. 27.↵
    1. Fanto M,
    2. Peragallo MS,
    3. Pietrosanti M,
    4. Di Rosa R,
    5. Picchianti Diamanti A,
    6. Salemi S,
    7. et al.

    Risk of malignancy in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under immunosuppressive therapy: a single-center experience. Intern Emerg Med 2016;11:31–40.

    OpenUrl
28. 28.↵
    1. Sarmiento-Monroy JC,
    2. Amaya-Amaya J,
    3. Espinosa-Serna JS,
    4. Herrera-Diaz C,
    5. Anaya JM,
    6. Rojas-Villarraga A

    . Cardiovascular disease in rheumatoid arthritis: a systematic literature review in Latin America. Arthritis 2012;2012:371909.

    OpenUrlPubMed
29. 29.↵
    1. Gomes CM,
    2. Terreri MT,
    3. Moraes-Pinto MI,
    4. Barbosa C,
    5. Machado NP,
    6. Melo MR,
    7. et al.

    Incidence of active mycobacterial infections in Brazilian patients with chronic inflammatory arthritis and negative evaluation for latent tuberculosis infection at baseline - A longitudinal analysis after using TNFa blockers. Mem Inst Oswaldo Cruz 2015;110:921–8.

    OpenUrl